



## Phathom Pharmaceuticals to Participate in Upcoming Investor Healthcare Conferences

November 3, 2022

FLORHAM PARK, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, announced today that members of its management team will participate in upcoming investor conferences:

### Guggenheim Healthcare Talks: 4th Annual Neuro/Immunology Conference

- Presentation Date: November 14, 2022
- Presentation Time: 2:45 PM ET

### Jefferies London Healthcare Conference

- Presentation Date: November 16, 2022
- Presentation Time: 9:10 am BST / 4:10 am ET

### 5th Annual Evercore ISI HealthCONx Conference

- Presentation Date: December 1, 2022
- Presentation Time: 1:25 PM ET

Company management will also participate in one-on-one meetings throughout the duration of each conference.

To access the live webcast and archived recordings of the presentations, visit the News & Events section of the Phathom website at <https://investors.phathompharma.com/news-events/events-and-presentations>. The recordings will be available for 90 days following the event.

### **About Phathom Pharmaceuticals, Inc.**

Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB). Vonoprazan-based regimens are approved in the U.S. as part of a co-packaged product in combination with antibiotics for the treatment of *H. pylori* infection in adults, marketed as VOQUEZNA™ TRIPLE PAK™ (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA™ DUAL PAK™ (vonoprazan, amoxicillin). Phathom has a New Drug Application under review by the FDA for vonoprazan in erosive esophagitis (EE) and is studying the use of vonoprazan for the treatment of non-erosive reflux disease (NERD). For more information about Phathom, visit the Company's website at [www.phathompharma.com](http://www.phathompharma.com) and follow the Company on [LinkedIn](#) and [Twitter](#).

### **MEDIA AND INVESTOR CONTACT:**

Nick Benedetto

1-877-742-8466

[media@phathompharma.com](mailto:media@phathompharma.com)

[ir@phathompharma.com](mailto:ir@phathompharma.com)

© 2022 Phathom Pharmaceuticals. All rights reserved.

VOQUEZNA, VOQUEZNA TRIPLE PAK, VOQUEZNA DUAL PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks or trademarks of Phathom Pharmaceuticals, Inc.